<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19651921</article-id><article-id pub-id-type="pmc">2768202</article-id><article-id pub-id-type="publisher-id">0959</article-id><article-id pub-id-type="doi">10.2337/dc09-0959</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Pathophysiology/Complications</subject></subj-group></subj-group></article-categories><title-group><article-title>Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes</article-title><subtitle>New results from the ADVANCE trial</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zoungas</surname><given-names>Sophia</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>de Galan</surname><given-names>Bastiaan E.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ninomiya</surname><given-names>Toshiharu</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grobbee</surname><given-names>Diederick</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hamet</surname><given-names>Pavel</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heller</surname><given-names>Simon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>MacMahon</surname><given-names>Stephen</given-names></name><degrees>DSC, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marre</surname><given-names>Michel</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Neal</surname><given-names>Bruce</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Anushka</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Woodward</surname><given-names>Mark</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chalmers</surname><given-names>John</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of the ADVANCE Collaborative Group<xref ref-type="author-notes" rid="FN1">*</xref></collab></contrib><aff id="aff1"><sup>1</sup>The George Institute for International Health, University of Sydney, Sydney, New South Wales, Australia; </aff><aff id="aff2"><sup>2</sup>Monash University, Melbourne, Victoria, Australia; </aff><aff id="aff3"><sup>3</sup>Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; </aff><aff id="aff4"><sup>4</sup>Julius Centre for Health Sciences and Primary Care, University Medical Centre, Utrecht, the Netherlands; </aff><aff id="aff5"><sup>5</sup>Centre Hospitalier de l'Universit&#x000e9; de Montreal and Universit&#x000e9; de Montreal, Montreal, Quebec, Canada; </aff><aff id="aff6"><sup>6</sup>University of Sheffield and Sheffield Teaching Hospitals, National Health Service Foundation Trust, Sheffield, U.K.; </aff><aff id="aff7"><sup>7</sup>H&#x000f4;pital Bichat-Claude Bernard and Universit&#x000e9; Paris 7, Paris, France; </aff><aff id="aff8"><sup>8</sup>Mount Sinai School of Medicine, New York, New York.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Sophia Zoungas, <email>szoungas@george.org.au</email>.</corresp><fn fn-type="other" id="FN1"><p>*All members of the ADVANCE Collaborative Group have been listed in full previously (<xref ref-type="bibr" rid="B8">8</xref>). Additional authors can be found in an online appendix.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>3</day><month>8</month><year>2009</year></pub-date><volume>32</volume><issue>11</issue><fpage>2068</fpage><lpage>2074</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 by the American Diabetes Association.</copyright-statement><license license-type="open-access"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc01109002068.pdf"/><abstract><sec><title>OBJECTIVE</title><p>To assess the magnitude and independence of the effects of routine blood pressure lowering and intensive glucose control on clinical outcomes in patients with long-standing type 2 diabetes.</p></sec><sec><title>RESEARCH DESIGN AND METHODS</title><p>This was a multicenter, factorial randomized trial of perindopril-indapamide versus placebo (double-blind comparison) and intensive glucose control with a gliclazide MR&#x02013;based regimen (target A1C &#x02264;6.5%) versus standard glucose control (open comparison) in 11,140 participants with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. Annual event rates and risks of major macrovascular and microvascular events considered jointly and separately, renal events, and death during an average 4.3 years of follow-up were assessed, using Cox proportional hazards models.</p></sec><sec><title>RESULTS</title><p>There was no interaction between the effects of routine blood pressure lowering and intensive glucose control for any of the prespecified clinical outcomes (all <italic>P</italic> &#x0003e; 0.1): the separate effects of the two interventions for the renal outcomes and death appeared to be additive on the log scale. Compared with neither intervention, combination treatment reduced the risk of new or worsening nephropathy by 33% (95% CI 12&#x02013;50%, <italic>P</italic> = 0.005), new onset of macroalbuminuria by 54% (35&#x02013;68%, <italic>P</italic> &#x0003c; 0.0001), and new onset of microalbuminuria by 26% (17&#x02013;34%). Combination treatment was associated with an 18% reduction in the risk of all-cause death (1&#x02013;32%, <italic>P</italic> = 0.04).</p></sec><sec><title>CONCLUSIONS</title><p>The effects of routine blood pressure lowering and intensive glucose control were independent of one another. When combined, they produced additional reductions in clinically relevant outcomes.</p></sec></abstract></article-meta></front><body><p>Type 2 diabetes affects &#x0003e;240 million people worldwide and significantly contributes to the global burden of vascular disease, of which both blood pressure and glucose are important determinants (<xref ref-type="bibr" rid="B1">1</xref>). Large-scale, randomized controlled trials have clearly documented the benefits of blood pressure&#x02013;lowering treatment on the risk of macrovascular and microvascular complications and on survival among patients with type 2 diabetes (<xref ref-type="bibr" rid="B2">2</xref><xref ref-type="bibr" rid="B3"/>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>). Intensive glucose control has been shown to reduce the risk of microvascular complications (<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6"/><xref ref-type="bibr" rid="B7"/>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>), although it did not improve patient survival or alter the course of macrovascular complications in the first 3&#x02013;10 years (<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8"/><xref ref-type="bibr" rid="B9"/>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>). Current guidelines recommend a multifactorial approach with simultaneous targeting of elevated blood pressure and glucose levels in individuals with type 2 diabetes (<xref ref-type="bibr" rid="B11">11</xref><xref ref-type="bibr" rid="B12"/>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>). However, it is not known whether combining blood pressure lowering and glucose control can reduce the risk of vascular complications to a greater extent than either treatment alone.</p><p>Results from the UK Prospective Diabetes Study (UKPDS) have suggested that the effects of blood pressure&#x02013; and glucose-lowering interventions might be additive (<xref ref-type="bibr" rid="B14">14</xref>). In post hoc analyses, the associations between vascular outcomes and systolic blood pressure or A1C levels achieved during follow-up were independent, and there was a trend toward the greatest benefit with the combination of intensive blood pressure&#x02013; and glucose-lowering interventions (<xref ref-type="bibr" rid="B14">14</xref>). However, because only a small subset of hypertensive subjects received both interventions, the UKPDS had insufficient power to determine conclusively whether the effects of the treatments were additive in this group or in the broader population with type 2 diabetes. Moreover, the reported excess mortality in the intensive glucose control arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study compared with that for those randomized to standard glucose control has raised concerns about whether intensive glucose lowering could modify or even negate the benefits of blood pressure lowering in patients with type 2 diabetes (<xref ref-type="bibr" rid="B9">9</xref>).</p><p>Recently the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study, a large-scale, double-blind, randomized factorial trial among 11,140 people with type 2 diabetes, demonstrated the separate vascular benefits of routine blood pressure lowering with a fixed combination of perindopril and indapamide after 4.3 years of follow-up and of intensive glucose control, based on gliclazide MR, after 5 years of follow-up (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>). In this report, we present new analyses that explore the extent to which blood pressure&#x02013;lowering treatment and intensive glucose control provide independent and additive benefits with respect to vascular outcomes in patients with type 2 diabetes after 4.3 years of follow-up.</p><sec><title>RESEARCH DESIGN AND METHODS</title><p>ADVANCE was a factorial randomized controlled trial evaluating the effects of blood pressure lowering and intensive blood glucose control on vascular outcomes. Detailed descriptions of the study methods have been published previously (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B15">15</xref>). In brief, a total of 11,140 individuals with type 2 diabetes aged &#x02265;55 years, with a history of major macrovascular or microvascular disease or at least one other risk factor for vascular disease, were enrolled from 215 centers in 20 countries. There were no A1C or blood pressure inclusion criteria. Approval for the trial was obtained from each center's institutional review board, and all participants provided written informed consent. After a 6-week active run-in period with fixed-combination perindopril and indapamide (2 mg/0.625 mg), during which usual glucose control was continued, participants were randomly assigned, in a factorial design, to continued perindopril-indapamide (2 mg/0.625 mg for the first 3 months then 4 mg/1.25 mg thereafter) or matching placebo and to either an intensive glucose control strategy aiming for an A1C of &#x02264;6.5% or a standard glucose control strategy (target A1C levels defined by local guidelines) using a central, computer-based randomization service. Participants randomly assigned to intensive glucose control were given gliclazide MR (30&#x02013;120 mg daily) and other glucose-lowering drugs as required by their primary physicians (<xref ref-type="bibr" rid="B8">8</xref>). Participants randomly assigned to the standard control who were using gliclazide MR at study entry were required to substitute this with another sulfonylurea, if continued therapy was required (<xref ref-type="bibr" rid="B8">8</xref>).</p><sec><title>Outcomes and follow-up</title><p>The primary outcomes were a composite of macrovascular (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) and microvascular (new or worsening nephropathy or retinopathy) events, considered jointly and separately (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>). The secondary outcomes examined were death from all causes, cardiovascular death, major coronary events (death due to coronary heart disease [including sudden death] or nonfatal myocardial infarction), major cerebrovascular events (death due to cerebrovascular disease or nonfatal stroke), new or worsening nephropathy (requirement for renal replacement therapy, death from renal disease, development of macroalbuminuria, or a doubling of serum creatinine to a level of at least 200 &#x003bc;mol/l), new onset of microalbuminuria (urinary albumin-to-creatinine ratio 30&#x02013;300 &#x003bc;g/mg) and total renal events (defined post hoc as the composite of new or worsening nephropathy or new onset of microalbuminuria), and new or worsening retinopathy. Primary outcomes and all deaths were reviewed and validated by an independent end point adjudication committee blinded to treatment allocation (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>). For the purposes of this study, the joint effects of randomized treatments were studied after 4.3 years of follow up, that is, at completion of the blood pressure intervention, although the glucose-lowering intervention was completed after an average of 5 years.</p></sec><sec><title>Statistical analysis</title><p>Differences between randomized groups in blood pressure and A1C during follow-up were estimated using linear mixed models. Annual event rates were calculated with the person-years method. Combined treatment effects on study end points were estimated from unadjusted Cox proportional hazard models, using survival time to the first relevant end point in any individual patient, according to the principle of intention to treat. Only the first event of the relevant outcome type was included in each analysis. Participants were censored at their date of death, date of last visit (for those still alive at the end of follow-up), or date when last known to be alive (for those with unknown vital status). For each outcome, interactions between treatment effects were tested by adding interaction terms to the relevant Cox models and comparing the likelihood statistics for the models with and without interaction; this will thus be termed a test for an additive interaction here. However, because Cox models work on the logarithmic scale, the null hypothesis being tested is that the joint effect of the two treatments is the product of their individual effects, with all effects measured through hazard ratios (HRs) (<xref ref-type="bibr" rid="B16">16</xref>). All <italic>P</italic> values were calculated from two-tailed tests of statistical significance with a type I error rate of 5%. All analyses were performed using SAS (version 9.1).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline characteristics</title><p>The four treatment groups were well balanced for a range of baseline characteristics (<xref ref-type="table" rid="T1">Table 1</xref>). In all four groups, 32% of participants had a history of major macrovascular disease and 10% had a history of major microvascular disease. Mean duration of diabetes was 8 years, and mean entry A1C and blood pressure were 7.5% and 145/81 mmHg, respectively (<xref ref-type="table" rid="T1">Table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of randomized participants at baseline</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Intensive glucose and perindopril-indapamide</th><th align="center" rowspan="1" colspan="1">Standard glucose and perindopril-indapamide</th><th align="center" rowspan="1" colspan="1">Intensive glucose and placebo</th><th align="center" rowspan="1" colspan="1">Standard glucose and placebo</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic></td><td align="center" rowspan="1" colspan="1">2,783</td><td align="center" rowspan="1" colspan="1">2,786</td><td align="center" rowspan="1" colspan="1">2,788</td><td align="center" rowspan="1" colspan="1">2,783</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.8 &#x000b1; 6.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.8 &#x000b1; 6.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.7 &#x000b1; 6.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">65.8 &#x000b1; 6.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="char" char="(" rowspan="1" colspan="1">1,198 (43.0)</td><td align="char" char="(" rowspan="1" colspan="1">1,168 (41.9)</td><td align="char" char="(" rowspan="1" colspan="1">1,181 (42.4)</td><td align="char" char="(" rowspan="1" colspan="1">1,188 (42.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age when diabetes first diagnosed (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57.8 &#x000b1; 8.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57.9 &#x000b1; 8.9</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57.8 &#x000b1; 8.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">57.8 &#x000b1; 8.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes duration (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.0 &#x000b1; 6.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.0 &#x000b1; 6.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.8 &#x000b1; 6.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.0 &#x000b1; 6.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior vascular disease</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;History of major macrovascular disease</td><td align="char" char="(" rowspan="1" colspan="1">896 (32.2)</td><td align="char" char="(" rowspan="1" colspan="1">902 (32.4)</td><td align="char" char="(" rowspan="1" colspan="1">898 (32.2)</td><td align="char" char="(" rowspan="1" colspan="1">894 (32.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;History of myocardial infarction</td><td align="char" char="(" rowspan="1" colspan="1">339 (12.2)</td><td align="char" char="(" rowspan="1" colspan="1">339 (12.2)</td><td align="char" char="(" rowspan="1" colspan="1">329 (11.8)</td><td align="char" char="(" rowspan="1" colspan="1">327 (11.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;History of stroke</td><td align="char" char="(" rowspan="1" colspan="1">254 (9.1)</td><td align="char" char="(" rowspan="1" colspan="1">248 (8.9)</td><td align="char" char="(" rowspan="1" colspan="1">261 (9.4)</td><td align="char" char="(" rowspan="1" colspan="1">259 (9.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;History of major microvascular disease</td><td align="char" char="(" rowspan="1" colspan="1">281 (10.1)</td><td align="char" char="(" rowspan="1" colspan="1">287 (10.3)</td><td align="char" char="(" rowspan="1" colspan="1">288 (10.3)</td><td align="char" char="(" rowspan="1" colspan="1">296 (10.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;History of macroalbuminuria</td><td align="char" char="(" rowspan="1" colspan="1">94 (3.5)</td><td align="char" char="(" rowspan="1" colspan="1">103 (3.9)</td><td align="char" char="(" rowspan="1" colspan="1">93 (3.5)</td><td align="char" char="(" rowspan="1" colspan="1">111 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;History of microvascular eye disease</td><td align="char" char="(" rowspan="1" colspan="1">195 (7.0)</td><td align="char" char="(" rowspan="1" colspan="1">194 (7.0)</td><td align="char" char="(" rowspan="1" colspan="1">206 (7.4)</td><td align="char" char="(" rowspan="1" colspan="1">198 (7.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;History of microalbuminuria</td><td align="char" char="(" rowspan="1" colspan="1">726 (27.4)</td><td align="char" char="(" rowspan="1" colspan="1">715 (26.9)</td><td align="char" char="(" rowspan="1" colspan="1">711 (26.7)</td><td align="char" char="(" rowspan="1" colspan="1">710 (26.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose control</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;A1C concentration (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5 &#x000b1; 1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.6 &#x000b1; 1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5 &#x000b1; 1.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7.5 &#x000b1; 1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Fasting blood glucose (mmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.6 &#x000b1; 2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.5 &#x000b1; 2.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.5 &#x000b1; 2.7</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">8.4 &#x000b1; 2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Other major risk factors</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Systolic blood pressure (mmHg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145.3 &#x000b1; 22.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">144.8 &#x000b1; 21.6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">144.6 &#x000b1; 21.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">145.3 &#x000b1; 21.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Diastolic blood pressure (mmHg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80.9 &#x000b1; 11.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80.5 &#x000b1; 11.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80.6 &#x000b1; 11.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">80.5 &#x000b1; 10.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Currently treated hypertension</td><td align="char" char="(" rowspan="1" colspan="1">1,909 (68.6)</td><td align="char" char="(" rowspan="1" colspan="1">1,893 (67.9)</td><td align="char" char="(" rowspan="1" colspan="1">1,907 (68.4)</td><td align="char" char="(" rowspan="1" colspan="1">1,946 (69.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Serum total cholesterol (mmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 1.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5.2 &#x000b1; 1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Serum LDL cholesterol (mmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.1 &#x000b1; 1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.1 &#x000b1; 1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.1 &#x000b1; 1.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3.1 &#x000b1; 1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Serum HDL cholesterol (mmol/l)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1.3 &#x000b1; 0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Serum triglycerides (mmol/l)</td><td align="char" char="(" rowspan="1" colspan="1">1.6 (1.2&#x02013;2.3)</td><td align="char" char="(" rowspan="1" colspan="1">1.6 (1.2&#x02013;2.3)</td><td align="char" char="(" rowspan="1" colspan="1">1.6 (1.2&#x02013;2.4)</td><td align="char" char="(" rowspan="1" colspan="1">1.7 (1.2&#x02013;2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Urinary albumin-to-creatinine ratio (&#x003bc;g/mg)</td><td align="char" char="(" rowspan="1" colspan="1">15 (7&#x02013;40)</td><td align="char" char="(" rowspan="1" colspan="1">15 (7&#x02013;40)</td><td align="char" char="(" rowspan="1" colspan="1">15 (7&#x02013;39)</td><td align="char" char="(" rowspan="1" colspan="1">14 (7&#x02013;40)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;BMI (kg/m<sup>2</sup>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.4 &#x000b1; 5.1</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.3 &#x000b1; 5.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.4 &#x000b1; 5.2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">28.3 &#x000b1; 5.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Current smoking</td><td align="char" char="(" rowspan="1" colspan="1">387 (13.9)</td><td align="char" char="(" rowspan="1" colspan="1">346 (12.4)</td><td align="char" char="(" rowspan="1" colspan="1">406 (14.6)</td><td align="char" char="(" rowspan="1" colspan="1">411 (14.8)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are means &#x000b1; SD, <italic>n</italic> (%), or median (interquartile range).</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Characteristics during follow-up</title><p>At the end of 4.3 years of follow-up, use of concomitant treatment was similar among the four treatment groups (supplementary Table, available in an online appendix at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc09-0959/DC1">http://care.diabetesjournals.org/cgi/content/full/dc09-0959/DC1</ext-link>). Over the duration of 4.3 years, blood pressure was reduced by an average &#x000b1; SEM of 7.1 &#x000b1; 0.3 mmHg systolic and 2.9 &#x000b1; 0.2 mmHg diastolic blood pressure in patients assigned to joint treatment compared with those assigned to neither treatment (<italic>P</italic> &#x0003c; 0.001). Similarly, A1C was reduced by 0.61 &#x000b1; 0.02% after 4.3 years follow-up in patients assigned to joint treatment compared with those assigned to neither treatment (<italic>P</italic> &#x0003c; 0.001).</p></sec><sec><title>Joint effects of routine blood pressure lowering and intensive glucose control</title><p>The HRs for the combination of blood pressure lowering with perindopril-indapamide and intensive glucose control with gliclazide MR and for either active treatment compared with those for placebo and standard glucose control are shown for all clinical outcomes in <xref ref-type="table" rid="T2">Table 2</xref>. There was no interaction between the effects of routine blood pressure lowering and intensive glucose control for any of the prespecified clinical end points (all <italic>P</italic> &#x0003e; 0.1), indicating that the effects of these two interventions were independent.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Joint effects of routine blood pressure lowering and intensive glucose control on all clinical outcomes</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1"/><th align="center" colspan="4" rowspan="1">Randomized treatments<hr/></th><th align="center" rowspan="2" colspan="1"><italic>P</italic><sub>interaction</sub></th></tr><tr><th align="center" rowspan="1" colspan="1">Intensive glucose and perindopril-indapamide</th><th align="center" rowspan="1" colspan="1">Standard glucose and perindopril-indapamide</th><th align="center" rowspan="1" colspan="1">Intensive glucose and placebo</th><th align="center" rowspan="1" colspan="1">Standard glucose and placebo</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1"><italic>n</italic></td><td align="char" char="." rowspan="1" colspan="1">2,783</td><td align="char" char="." rowspan="1" colspan="1">2,786</td><td align="char" char="." rowspan="1" colspan="1">2,788</td><td align="char" char="." rowspan="1" colspan="1">2,783</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Primary outcomes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Combined major microvascular and macrovascular events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">431</td><td align="char" char="." rowspan="1" colspan="1">430</td><td align="char" char="." rowspan="1" colspan="1">440</td><td align="char" char="." rowspan="1" colspan="1">498</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.85 (0.75&#x02013;0.97)</td><td align="char" char="(" rowspan="1" colspan="1">0.85 (0.74&#x02013;0.96)</td><td align="char" char="(" rowspan="1" colspan="1">0.87 (0.77&#x02013;0.99)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Major microvascular events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">213</td><td align="char" char="." rowspan="1" colspan="1">226</td><td align="char" char="." rowspan="1" colspan="1">217</td><td align="char" char="." rowspan="1" colspan="1">260</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.81 (0.68&#x02013;0.97)</td><td align="char" char="(" rowspan="1" colspan="1">0.85 (0.72&#x02013;1.02)</td><td align="char" char="(" rowspan="1" colspan="1">0.83 (0.69&#x02013;0.99)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Major macrovascular events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">246</td><td align="char" char="." rowspan="1" colspan="1">234</td><td align="char" char="." rowspan="1" colspan="1">255</td><td align="char" char="." rowspan="1" colspan="1">265</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.77&#x02013;1.10)</td><td align="char" char="(" rowspan="1" colspan="1">0.87 (0.73&#x02013;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">0.96 (0.81&#x02013;1.14)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Other outcomes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Death from any cause</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">198</td><td align="char" char="." rowspan="1" colspan="1">210</td><td align="char" char="." rowspan="1" colspan="1">231</td><td align="char" char="." rowspan="1" colspan="1">240</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.82 (0.68&#x02013;0.99)</td><td align="char" char="(" rowspan="1" colspan="1">0.87 (0.72&#x02013;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">0.96 (0.80&#x02013;1.15)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Death from cardiovascular causes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">104</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char="." rowspan="1" colspan="1">121</td><td align="char" char="." rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.76 (0.59&#x02013;0.98)</td><td align="char" char="(" rowspan="1" colspan="1">0.78 (0.60&#x02013;1.00)</td><td align="char" char="(" rowspan="1" colspan="1">0.89 (0.70&#x02013;1.14)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Major coronary heart events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">133</td><td align="char" char="." rowspan="1" colspan="1">132</td><td align="char" char="." rowspan="1" colspan="1">139</td><td align="char" char="." rowspan="1" colspan="1">155</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.77&#x02013;1.10)</td><td align="char" char="(" rowspan="1" colspan="1">0.87 (0.73&#x02013;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">0.90 (0.71&#x02013;1.13)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Major cerebrovascular events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">111</td><td align="char" char="." rowspan="1" colspan="1">104</td><td align="char" char="." rowspan="1" colspan="1">111</td><td align="char" char="." rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">1.03 (0.79&#x02013;1.35)</td><td align="char" char="(" rowspan="1" colspan="1">0.96 (0.73&#x02013;1.26)</td><td align="char" char="(" rowspan="1" colspan="1">1.03 (0.79&#x02013;1.35)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;All renal events</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">590</td><td align="char" char="." rowspan="1" colspan="1">630</td><td align="char" char="." rowspan="1" colspan="1">686</td><td align="char" char="." rowspan="1" colspan="1">777</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.72 (0.65&#x02013;081)</td><td align="char" char="(" rowspan="1" colspan="1">0.77 (0.69&#x02013;0.85)</td><td align="char" char="(" rowspan="1" colspan="1">0.88 (0.79&#x02013;0.97)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;New or worsening nephropathy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">81</td><td align="char" char="." rowspan="1" colspan="1">100</td><td align="char" char="." rowspan="1" colspan="1">96</td><td align="char" char="." rowspan="1" colspan="1">120</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.67 (0.50&#x02013;0.88)</td><td align="char" char="(" rowspan="1" colspan="1">0.82 (0.63&#x02013;1.07)</td><td align="char" char="(" rowspan="1" colspan="1">0.80 (0.61&#x02013;1.05)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;New or worsening retinopathy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">147</td><td align="char" char="." rowspan="1" colspan="1">142</td><td align="char" char="." rowspan="1" colspan="1">133</td><td align="char" char="." rowspan="1" colspan="1">153</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.96 (0.76&#x02013;1.20)</td><td align="char" char="(" rowspan="1" colspan="1">0.92 (0.73&#x02013;1.16)</td><td align="char" char="(" rowspan="1" colspan="1">0.86 (0.69&#x02013;1.09)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;New onset of microalbuminuria</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">525</td><td align="char" char="." rowspan="1" colspan="1">542</td><td align="char" char="." rowspan="1" colspan="1">605</td><td align="char" char="." rowspan="1" colspan="1">673</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.75 (0.67&#x02013;0.84)</td><td align="char" char="(" rowspan="1" colspan="1">0.77 (0.68&#x02013;0.86)</td><td align="char" char="(" rowspan="1" colspan="1">0.90 (0.80&#x02013;100)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;New onset of macroalbuminuria</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;No. events</td><td align="char" char="." rowspan="1" colspan="1">44</td><td align="char" char="." rowspan="1" colspan="1">74</td><td align="char" char="." rowspan="1" colspan="1">73</td><td align="char" char="." rowspan="1" colspan="1">95</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;HR (95% CI)</td><td align="char" char="(" rowspan="1" colspan="1">0.46 (0.32&#x02013;0.65)</td><td align="char" char="(" rowspan="1" colspan="1">0.77 (0.56&#x02013;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">0.77 (0.57&#x02013;1.04)</td><td align="char" char="(" rowspan="1" colspan="1">1.00 (reference)</td><td align="char" char="." rowspan="1" colspan="1">0.30</td></tr></tbody></table></table-wrap><p>A total of 1,799 participants had a major macrovascular or microvascular event during follow-up: 431 (15.5%) in the joint treatment group and 498 (17.9%) in the group that received neither active intervention, a relative risk reduction of 15% (95% CI 3&#x02013;25%, <italic>P</italic> = 0.02). Compared with neither active intervention, combined treatment reduced the risk of microvascular events by 19% (3&#x02013;32%, <italic>P</italic> = 0.02) but had no significant effect on the incidence of macrovascular events (8% [&#x02212;10 to 23%], <italic>P</italic> = 0.35).</p><p>A total of 2,683 participants had a major renal event during follow-up: 590 (21.2%) in the joint treatment group and 777 (27.9%) in the group that received neither active intervention. Compared with neither active intervention, combined treatment reduced the risk of all renal events by 28% (95% CI 19&#x02013;35%, <italic>P</italic> &#x0003c; 0.0001), which included a 33% reduction in the risk of new or worsening nephropathy (12&#x02013;50%, <italic>P</italic> = 0.005), a 54% reduction in the risk of new onset of macroalbuminuria (35&#x02013;68%, <italic>P</italic> &#x0003c; 0.0001), and a 25% reduction in the risk of new onset of microalbuminuria (16&#x02013;33%, <italic>P</italic> &#x0003c; 0.001). The effects of each intervention on all renal events were intermediate between those of joint treatment and neither active intervention. When considered separately, the effects of the two interventions were additive on the log scale, and the effect of each intervention was not altered by the other treatment (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Relative effects of routine blood pressure&#x02013;lowering and intensive glucose control strategy on all prespecified renal events. The effects of treatment (HRs) were estimated from unadjusted Cox proportional hazards models that used all available data at 4.3 years of follow-up. The diamonds incorporate the point estimates, represented by the vertical dashed lines, and the 95% CIs of the overall effects within categories; for subcategories, black squares represent point estimates (with the area of each square proportional to the inverse variance of each estimate), and horizontal lines represent 95% CIs. The HRs and relative risk reductions are given for intensive glucose control compared with standard glucose control in the blood pressure&#x02013;lowering arm and for perindopril-indapamide (Per-Ind) compared with placebo in the glucose-lowering arm.</p></caption><graphic xlink:href="zdc0110978750001"/></fig><p>A total of 879 participants died during follow-up: 198 (7.1%) in the joint treatment group and 240 (8.6%) in the group that received neither active intervention. Compared with those in neither active intervention, those allocated to joint treatment had a significantly lower annual mortality rate (relative risk reduction 18% [95% CI 1&#x02013;32%], <italic>P</italic> = 0.04) with the effects of the two treatments being independent of each other (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Combined effects of routine blood pressure&#x02013;lowering and intensive glucose control strategy on the incidence of death from any cause. Incidence of death from any cause is presented as the annual event rate (percent) by the four randomized treatment groups: intensive glucose control and perindopril-indapamide (Per-Ind), standard glucose control and perindopril-indapamide, intensive glucose control and placebo, and standard glucose control and placebo. The effects of treatment (HRs and <italic>P</italic> values) were estimated from unadjusted Cox proportional hazards models that used all available data at 4.3 years of follow-up. The diamond incorporates the point estimate, represented by the vertical dashed line and the 95% CI of the overall effect. The HRs and relative risk reductions (RRRs) are given for intensive glucose control compared with standard glucose control in the blood pressure (BP)-lowering arm and for perindopril-indapamide compared with placebo in the glucose-lowering arm.</p></caption><graphic xlink:href="zdc0110978750002"/></fig></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>The ADVANCE trial has reported the separate beneficial effects of routine blood pressure lowering with perindopril-indapamide and intensive glucose control with a gliclazide MR&#x02013;based regimen on a range of vascular complications in patients with type 2 diabetes (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>). In the present analyses we show that the combined effect of both treatments was at least as great as the effect of either treatment alone for all clinical outcomes and appeared to be greater for some. This finding was most clearly apparent where both blood pressure lowering and intensive glucose control had separate significant beneficial effects, as was observed for all renal events and the components of new or worsening nephropathy, new onset of microalbuminuria, and new onset of macroalbuminuria (<xref ref-type="table" rid="T2">Table 2</xref>). Where a separately significant beneficial effect was observed only for blood pressure lowering (as for all-cause mortality and cardiovascular death), the addition of intensive glucose control did not negate that effect. In fact, for all-cause mortality (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F2">Fig. 2</xref>) and cardiovascular death (<xref ref-type="table" rid="T2">Table 2</xref>), the estimates of the effect size for the joint intervention were slightly greater than they were for blood pressure lowering alone. These findings provide considerable reassurance that the widely used clinical approach of joint management of blood pressure and glucose in patients with type 2 diabetes is both appropriate and effective.</p><p>Our findings support and strengthen those of the UKPDS (<xref ref-type="bibr" rid="B14">14</xref>) and provide further evidence for the benefits of a multifactorial treatment approach that includes blood pressure lowering and intensive glucose control in patients with type 2 diabetes. The previously reported benefits of multifactorial risk management in the STENO 2 study were obtained through a combination of optimal blood pressure, glucose control, lipid modification, and antiplatelet therapy, although only 20% of participants achieved A1C levels of &#x0003c;7% (<xref ref-type="bibr" rid="B11">11</xref>). Our data show that intensification of glycemic control to achieve A1C levels of &#x02264;6.5% augments the benefits obtained with blood pressure&#x02013;lowering treatment, particularly with respect to renal events. Our study also shows that such an approach has benefits not only for individuals with type 2 diabetes who also have hypertension (<xref ref-type="bibr" rid="B14">14</xref>) or microalbuminuria (<xref ref-type="bibr" rid="B11">11</xref>) but for a much broader cross-section of the population with type 2 diabetes.</p><p>The substantial renal benefits observed in both arms of the ADVANCE trial and magnified in the group receiving both interventions may also translate into future cardiovascular benefits. Elevated levels of albuminuria have clearly been demonstrated to be a risk factor for cardiovascular disease in patients with type 2 diabetes (<xref ref-type="bibr" rid="B17">17</xref>), with current screening strategies aimed to identify affected patients so that appropriate preventive treatments may be introduced. Recent studies have suggested that treatment of albuminuria per se may reduce cardiovascular events (<xref ref-type="bibr" rid="B18">18</xref>). Long-term follow-up of the UKPDS study (<xref ref-type="bibr" rid="B19">19</xref>) has also demonstrated that the cardiovascular and mortality benefits of intensive glucose control emerge over time. The combined treatment strategy used in ADVANCE would therefore be anticipated to further reduce cardiovascular risk in the long term.</p><p>In the ACCORD study, intensive glucose control increased the risk of death (<xref ref-type="bibr" rid="B9">9</xref>). However, the overall mortality rate was much lower than predicted, probably as a consequence of the factorial study design that included intensive blood pressure&#x02013; and lipid-lowering interventions. Our analyses provide no evidence of such an increase in mortality either in the glucose-lowering arm of the ADVANCE trial as reported previously (<xref ref-type="bibr" rid="B8">8</xref>) or in the present analyses. On the contrary, the combination of both active interventions compared with neither active intervention significantly reduced the risk of all-cause and cardiovascular mortality. There was also no indication that the benefits of routine blood pressure lowering were offset by the intensive glucose control intervention. If anything, the magnitude of risk reduction was somewhat greater in the group receiving both interventions than that observed in the group receiving routine blood pressure lowering alone. It is noteworthy that the intensive glucose control strategies applied in ADVANCE and in ACCORD differed substantially in the way the glucose target was achieved (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>). Our results indicate that intensive glucose control can be implemented safely through a conventional approach, using the gliclazide MR&#x02013;based regimen and stepwise increase in oral agents and, eventually, basal insulin (<xref ref-type="bibr" rid="B8">8</xref>).</p><p>Although we found no evidence for an interaction between the blood pressure&#x02013; and glucose-lowering interventions for any of the outcomes, we are unable to fully exclude the presence of an interaction, particularly for some of the less common outcomes. Exclusion of any interaction between the two interventions of the ADVANCE trial would have required a sample size 4 times as large to be adequately powered (<xref ref-type="bibr" rid="B20">20</xref>). The absence of an interaction is further supported by observational data demonstrating that associations of blood pressure levels and measures of glycemic control with the risks of mortality and coronary heart disease in patients with type 2 diabetes are independent and additive (<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>).</p><p>When the treatments were not demonstrated to have separate significant benefits, as for macrovascular events, such effects were also not observed with combined treatment. One possible explanation is the relatively short length of study follow-up. This may particularly influence the effect of the glucose-lowering strategy for which the rate of macrovascular events only began to diverge in the last 12 months of the average 5-year period of follow-up, whereas the present analyses were limited to 4.3 years of follow up (<xref ref-type="bibr" rid="B8">8</xref>). The resultant loss of a large number of events that occurred with prolongation of the randomized glucose intervention therefore limited the statistical power to detect significant effects. In addition, the lower-than-anticipated event rates, possibly reflecting the comprehensive background management of cardiovascular risk in both arms (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>), and less-than-projected separation in A1C between the glucose treatment groups may have further reduced the ability to detect an effect reliably. The recent report from the 10-year post-trial follow-up of the UKPDS cohort of significant long-term benefits observed with intensive glucose control for macrovascular events (<xref ref-type="bibr" rid="B19">19</xref>) suggests that the ADVANCE trial may have required much longer follow-up to demonstrate clear benefits of intensive glucose (<xref ref-type="bibr" rid="B8">8</xref>) or combined treatment for this outcome.</p><p>In summary, the ADVANCE trial has demonstrated that a combined approach of routine blood pressure lowering and intensive glucose control resulted in substantial reductions in major renal events and all-cause death. For the major renal outcomes, the separately significant beneficial effects of the two interventions were additive. This suggests that the multifactorial management of type 2 diabetes should incorporate routine blood pressure lowering and more intensive glucose control to reduce the burden of adverse clinical sequelae in individuals with established diabetes.</p></sec>
      <sec sec-type="supplementary-material">
         <title>Supplementary Material</title>
         <supplementary-material id="PMC_1" content-type="local-data">
            <caption>
               <title>Online-Only Appendix</title>
            </caption>
            <media mimetype="text" mime-subtype="html" xlink:href="supp_32_11_2068__index.html"/>
            <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
                   xlink:href="supp_dc09-0959_dc09-0959_Online_Appendix.pdf"/>
         </supplementary-material>
      </sec>
   </body><back><fn-group><fn fn-type="other"><p>Clinical trial reg. no. NCT00145925, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn fn-type="other"><p>This study was designed, conducted, analyzed, and interpreted by the investigators independently of all sponsors.</p></fn><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked &#x0201c;advertisement&#x0201d; in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>The ADVANCE trial was funded by grants from the National Health and Medical Research Council of Australia and Institut de Recherches Internationales Servier. S.Z. was supported by a National Health and Medical Research Council of Australia Health Professional Research Fellowship. T.N. was supported by a fellowship awarded by the Banyu Life Science Foundation and by an International Society of Hypertension Visiting Postdoctoral Fellowship awarded by the Foundation for High Blood Pressure Research Council of Australia. A.P. was supported by a National Heart Foundation of Australia Career Development award.</p><p>S.Z. reports being a member of an advisory board for Merck and receiving lecture fees from Servier, GlaxoSmithKline, and sanofi-aventis and grant support from Novo Nordisk and Pfizer. B.E.d.G. reports receiving lecture fees from Servier. D.G. reports receiving lecture fees from Servier and consulting and lecture fees and grant support from Pfizer, AstraZeneca, Novartis, and sanofi-aventis. P.H. reports receiving consulting or lecture fees from Servier, Neurochem, Prognomix, Medpharmgene, Novartis, Bristol-Myers Squibb, and Pfizer. S.H. reports receiving consulting and lecture fees from Novo Nordisk, Eli Lilly, Amylin, Servier, and Merck and grant support from Novo Nordisk and GW Pharmaceuticals. S.M. reports being a member of advisory boards for Servier, Pfizer, and Novartis and receiving lecture fees from Servier and Pfizer and grant support from Servier, Pfizer, and Novartis. M.M. reports receiving lecture fees from Servier and being a member of advisory boards for Servier, Novo Nordisk, and sanofi-aventis. B.N. reports receiving lecture fees from Servier and GlaxoSmithKline and grant support from Pfizer. A.P. reports receiving lecture fees from Servier, Pfizer, and Abbott and grant support from Servier, Pfizer. and sanofi-aventis. M.W. reports receiving lecture fees from Servier and Pfizer and grant support from Pfizer and sanofi-aventis. J.C. reports being a member of an advisory board for Servier and receiving lecturing fees from Servier, Pfizer, and Daiichi and grant support from Servier. No other potential conflicts of interest relevant to this article were reported.</p><p>Parts of this study were presented in abstract form at the annual meeting of the American Society of Nephrology, Philadelphia, Pennsylvania, 4&#x02013;9 November 2008.</p><p>We thank the patients and all the investigators at the participating centers.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="book"><collab>International Diabetes Federation</collab> <source>Diabetes Atlas</source> <edition>3rd ed.</edition><publisher-loc>Brussels</publisher-loc>, <publisher-name>International Diabetes Federation</publisher-name>, <year>2006</year></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><collab>UK Prospective Diabetes Study Group</collab> <article-title>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38</article-title>. <source>BMJ</source><year>1998</year>;<volume>317</volume>:<fpage>703</fpage>&#x02013;<lpage>713</lpage><pub-id pub-id-type="pmid">9732337</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><collab>Heart Outcomes Prevention Evaluation (HOPE) Study Investigators</collab> <article-title>Effects of cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy</article-title>. <source>Lancet</source><year>2000</year>;<volume>355</volume>: <fpage>253</fpage>&#x02013;<lpage>259</lpage><pub-id pub-id-type="pmid">10675071</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><name><surname>Harrap</surname><given-names>S</given-names></name><name><surname>Poulter</surname><given-names>N</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Hamet</surname><given-names>P</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>LS</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Pan</surname><given-names>CY</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name></person-group>: <article-title>Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</article-title>. <source>Lancet</source><year>2007</year>;<volume>370</volume>:<fpage>829</fpage>&#x02013;<lpage>840</lpage><pub-id pub-id-type="pmid">17765963</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkubo</surname><given-names>Y</given-names></name><name><surname>Kishikawa</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Isami</surname><given-names>S</given-names></name><name><surname>Motoyoshi</surname><given-names>S</given-names></name><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Furuyoshi</surname><given-names>N</given-names></name><name><surname>Shichiri</surname><given-names>M</given-names></name></person-group>: <article-title>Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study</article-title>. <source>Diabetes Res Clin Pract</source><year>1995</year>;<volume>28</volume>:<fpage>103</fpage>&#x02013;<lpage>117</lpage><pub-id pub-id-type="pmid">7587918</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shichiri</surname><given-names>M</given-names></name><name><surname>Kishikawa</surname><given-names>H</given-names></name><name><surname>Ohkubo</surname><given-names>Y</given-names></name><name><surname>Wake</surname><given-names>N</given-names></name></person-group>: <article-title>Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetes patients</article-title>. <source>Diabetes Care</source><year>2000</year>;<volume>23</volume>(<issue>Suppl. 2</issue>):<fpage>B21</fpage>&#x02013;<lpage>B29</lpage><pub-id pub-id-type="pmid">10860187</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab> <article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</article-title>. <source>Lancet</source><year>1998</year>;<volume>352</volume>:<fpage>837</fpage>&#x02013;<lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><collab>The ADVANCE Collaborative Group</collab> <article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2560</fpage>&#x02013;<lpage>2572</lpage><pub-id pub-id-type="pmid">18539916</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><collab>The Action to Control Cardiovascular Risk in Diabetes Study Group</collab> <article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>358</volume>:<fpage>2543</fpage>&#x02013;<lpage>2553</lpage></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>W</given-names></name><name><surname>Abraira</surname><given-names>C</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Reda</surname><given-names>D</given-names></name><name><surname>Emanuele</surname><given-names>N</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name><name><surname>Zieve</surname><given-names>FJ</given-names></name><name><surname>Marks</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>SN</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><name><surname>Warren</surname><given-names>SR</given-names></name><name><surname>Goldman</surname><given-names>S</given-names></name><name><surname>McCarren</surname><given-names>M</given-names></name><name><surname>Vitek</surname><given-names>ME</given-names></name><name><surname>Henderson</surname><given-names>WG</given-names></name><name><surname>Huang</surname><given-names>GD</given-names></name></person-group><collab>VADT Investigators</collab> <article-title>Glucose control and vascular complications in veterans with type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2009</year>;<volume>360</volume>:<fpage>129</fpage>&#x02013;<lpage>139</lpage><pub-id pub-id-type="pmid">19092145</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaede</surname><given-names>P</given-names></name><name><surname>Vedel</surname><given-names>P</given-names></name><name><surname>Larsen</surname><given-names>N</given-names></name><name><surname>Jensen</surname><given-names>GV</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Perdersen</surname><given-names>O</given-names></name></person-group>: <article-title>Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2003</year>;<volume>348</volume>:<fpage>383</fpage>&#x02013;<lpage>393</lpage><pub-id pub-id-type="pmid">12556541</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><collab>American Diabetes Association</collab> <article-title>Standards of medical care in diabetes&#x02014;2008</article-title>. <source>Diabetes Care</source><year>2008</year>;<volume>31</volume>(<issue>Suppl. 1</issue>):<fpage>S12</fpage>&#x02013;<lpage>S54</lpage><pub-id pub-id-type="pmid">18165335</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="book"><collab>IDF Clinical Guidelines Task Force</collab> <source>Global Guideline for Type 2 Diabetes</source> <publisher-loc>Brussels</publisher-loc>, <publisher-name>International Diabetes Federation</publisher-name>, <year>2005</year></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group>: <article-title>Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)</article-title>. <source>Diabetologia</source><year>2006</year>;<volume>49</volume>:<fpage>1761</fpage>&#x02013;<lpage>1769</lpage><pub-id pub-id-type="pmid">16736131</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><collab>ADVANCE Management Committee</collab> <article-title>Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron MR controlled evaluation</article-title>. <source>Diabetologia</source><year>2001</year>;<volume>44</volume>:<fpage>1118</fpage>&#x02013;<lpage>1120</lpage><pub-id pub-id-type="pmid">11596665</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>M</given-names></name></person-group>: <article-title>epidemiology: study design and data analysis</article-title>. <edition>2nd ed.</edition><publisher-loc>Boca Raton, FL</publisher-loc>, <publisher-name>Chapman and Hall/CRC Press</publisher-name>, <year>2005</year></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Verdon</surname><given-names>C</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><name><surname>Barzi</surname><given-names>F</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Jardine</surname><given-names>M</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Turnbull</surname><given-names>F</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Craig</surname><given-names>J</given-names></name><name><surname>Huxley</surname><given-names>R</given-names></name></person-group>: <article-title>The relationship between proteinuria and coronary risk: a systematic review and meta-analysis</article-title>. <source>PLoS Med</source><year>2008</year>;<volume>5</volume>:<fpage>e207</fpage><pub-id pub-id-type="pmid">18942886</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Zeeuw</surname><given-names>D</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Keane</surname><given-names>WF</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shahinfar</surname><given-names>S</given-names></name><name><surname>Snapinn</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Brenner</surname><given-names>BM</given-names></name></person-group>: <article-title>Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy</article-title>. <source>Circulation</source><year>2004</year>;<volume>110</volume>:<fpage>921</fpage>&#x02013;<lpage>927</lpage><pub-id pub-id-type="pmid">15302780</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name></person-group>: <article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>1577</fpage>&#x02013;<lpage>1589</lpage><pub-id pub-id-type="pmid">18784090</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Piantadosi</surname><given-names>S</given-names></name></person-group>: <source>Clinical Trials: a Methodologic Perspective</source> <edition>2nd ed.</edition><publisher-loc>Hoboken, NJ</publisher-loc>, <publisher-name>John Wiley &#x00026; Sons</publisher-name>, <year>2005</year></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>J</given-names></name><name><surname>Vaccaro</surname><given-names>O</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Wentworth</surname><given-names>D</given-names></name></person-group>: <article-title>Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial</article-title>. <source>Diabetes Care</source><year>1993</year>;<volume>16</volume>:<fpage>434</fpage>&#x02013;<lpage>444</lpage><pub-id pub-id-type="pmid">8432214</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Julius</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Schwanebeck</surname><given-names>U</given-names></name><name><surname>Schmechel</surname><given-names>H</given-names></name><name><surname>Ziegelasch</surname><given-names>HJ</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name></person-group><article-title>DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow up</article-title>. <source>Diabetologia</source><year>1996</year>;<volume>39</volume>:<fpage>1577</fpage>&#x02013;<lpage>1583</lpage><pub-id pub-id-type="pmid">8960845</pub-id></mixed-citation></ref></ref-list></back></article>